Tailoring Treatment Approaches in Psoriasis Management - Episode 3
Incorporating Clinical Guidelines in Psoriasis Management
Panelists discuss how biologic therapies for psoriasis are increasingly considered earlier in treatment algorithms based on the American Academy of Dermatology-National Psoriasis Foundation (AAD-NPF) Guidelines and updated International Psoriasis Council (IPC) severity classifications, with decisions influenced by disease extent, impact on quality of life, presence of psoriatic arthritis, treatment history, patient preferences, and the recognition that prompt intervention with biologics can prevent disease progression and comorbidities in patients with moderate to severe disease.
Video content above is prompted by the following:
- Current treatment guidelines (AAD-NPF Guidelines) recommend biologic therapies for the management of moderate to severe psoriasis. When do you consider biologics for your patients?
- IPC updated severity classification
